Clinical illness as a marker for initiation of HIV antiretroviral therapy in a rural setting, Rakai, Uganda

International Journal of STD and AIDS

Volumn 17, Issue 2, 2006, Pages 116-120

  Spacek, Lisa A ^a   Gray, Ronald H ^b   Wawer, Maria J ^c   Sewankambo, Nelson K ^d   Serwadda, David ^d   Wabwire Mangen, Fred ^d   Kiwanuka, Noah ^e   Kigozi, Godfrey ^e   Nalugoda, Fred ^e   Quinn, Thomas C ^a,f  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c Joseph L Mailman School of Public Health ^*  (United States)

^d MAKERERE UNIVERSITY   (Uganda)

^e UGANDA VIRUS RESEARCH INSTITUTE   (Uganda)

^f NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

AIDS care; Algorithms; Antiretroviral therapy; Resource limited setting; Uganda

Indexed keywords

ANTIRETROVIRUS AGENT;

ADULT; ARTICLE; COHORT ANALYSIS; COMMUNITY; DEATH; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE MARKER; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RURAL AREA; SAMPLING; UGANDA; VIRUS LOAD; WORLD HEALTH ORGANIZATION;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ALGORITHMS; ANTI-HIV AGENTS; COHORT STUDIES; DISEASE PROGRESSION; HIV INFECTIONS; HIV-1; HUMANS; RETROSPECTIVE STUDIES; RURAL HEALTH; UGANDA; VIRAL LOAD;

EID: 33644560597     PISSN: 09564624     EISSN: None     Source Type: Journal    
DOI: 10.1258/095646206775455766     Document Type: Article

References (22)

1. World Health Organization. Scaling up Antiretroviral Therapy in Resource Limited Settings: Treatment Guidelines for a Public Health Approach. Geneva: WHO, 2003 Available at: [www.who.int/hiv/pub/prev_care/en/arvrevision2003en.pdf]
2. The WHO International Collaborating Group for the Study of the WHO Staging System. Proposed 'World Health Organization Staging System for HIV Infection and Disease': preliminary testing by an international collaborative cross-sectional study. AIDS 1993;7:711-18
3. Mellors JW, Munoz A, Giorgi JV, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997;126:946-54
4. Lyles RH, Muñoz A, Yamashita TE, et al. Natural history of human immunodeficiency virus type 1 viremia after seroconversion and proximal to AIDS in a large cohort of homosexual men. Multicenter AIDS Cohort Study. J Infect Dis 2000;181:872-80
5. Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents. Rockville, MD: Department of Health and Human Services, 2002. Updated adult guidelines of October 6, 2005 are available at [www.aidsinfo.nih.gov/guidelines/ adult/AA_100605.pdf]
6. Blatt SP, Lucey CR, Butzin CA, Hendrix CW, Lucey DR. Total lymphocyte count as a predictor of absolute CD4+ count and CD4+ percentage in HIV-infected persons. JAMA 1993;269:622-6
7. Post FA, Wood R, Maartens G. CD4 and total lymphocyte counts as predictors of HIV disease progression. Quart J Med 1996;89:505-8
8. van der Ryst E, Kotze M, Joubert G, et al. Correlation among total lymphocyte count, absolute CD4+ count, and CD4+ percentage in a group of HIV-1-infected South African patients. J Acquir Immune Defic Syndr Hum Retrovirol 1998;19:238-44
9. Spacek LA, Griswold M, Quinn TC, Moore RD. Total lymphocyte count and hemoglobin combined in an algorithm to initiate the use of highly active antiretroviral therapy in resource-limited settings. AIDS 2003;17:1311-17
10. Kumarasamy N, Mahajan AP, Flanigan TP, et al. Total lymphocyte count (TLC) is a useful tool for the timing of opportunistic infection prophylaxis in India and other resource-constrained countries. J Acquir Immune Defic Syndr 2002;31:378-83
11. Mahajan AP, Hogan JW, Snyder B, et al. Changes in total lymphocyte count as a surrogate for changes in CD4 count following initiation of HAART: implications for monitoring in resource-limited settings. J Acquir Immune Defic Syndr 2004;36:567-75
12. Mekonnen Y, Dukers NH, Sanders E, et al. Simple markers for initiating antiretroviral therapy among HIV-infected Ethiopians. AIDS 2003;17:815-19
13. Wawer MJ, Sewankambo NK, Serwadda D, et al. Control of sexually transmitted diseases for AIDS prevention in Uganda: a randomized community trial. Rakai Project Study Group. Lancet 1999;353:525-35
14. World Health Organization. WHO case definitions for AIDS surveillance in adults and adolescents. Wkly Epidemiol Rev 1994;69:273-80
15. Malamba SS, Morgan D, Clayton T, Mayanja B, Okongo M, Whitworth J. The prognostic value of the World Health Organization staging system for HIV infection and disease in rural Uganda. AIDS 1999;13:2555-62
16. Donovan RM, Bush CE, Markowitz NP, Baxa DM, Saravolatz LD. Changes in virus load markers during AIDS-associated opportunistic diseases in human immunodeficiency virus-infected persons. J Infect Dis 1996;174:401-403
17. Sulkowski MS, Chaisson RE, Karp CL, Moore RD, Margolick JB, Quinn TC. The effect of acute infectious illnesses on plasma human immunodeficiency virus (HIV) type 1 load and the expression of serologic markers of immune activation among HIV-infected adults. J Infect Dis 1998;178:1642-8
18. Goletti D, Weissman D, Jackson RW, et al. Effect of Mycobacterium tuberculosis on HIV replication. Role of immune activation. J Immunol 1996;157:1271-8
19. Bush CE, Donovan RM, Markowitz NP, Kvale P, Saravolatz LD. A study of HIV RNA viral load in AIDS patients with bacterial pneumonia. J Acquir Immune Defic Syndr Hum Retrovirol 1996;13:23-6
20. Mole L, Ripich S, Margolis D, Holodniy M. The impact of active herpes simplex virus infection on human immunodeficiency virus load. J Infect Dis 1997;176:766-70
21. Chaisson RE, Gallant JE, Keruly JC, Moore RD. Impact of opportunistic disease on survival in patients with HIV infection. AIDS 1998;12:29-33
22. Whalen C, Horsburgh CR, Hom D, Lahart C, Simberkoff M, Ellner J. Accelerated course of human immunodeficiency virus infection after tuberculosis. Am J Resp Crit Care Med 1995;151:129-35